CTIBIOTECH

CTIBIOTECH™ is a pioneer and a world leader in the production of human tissues and bioassays using 3D bioprinting and additive manufacturing for biomedical, pharmaceutical, and dermatocosmetics research and development. For the last 15 years, CTIBIOTECH™ perfected, optimized and developed bespoke human tissue engineering technologies, and masters 3 methods to produce predictive bioassays based on human cells: - "Ex vivo" 3D human tissue culture: by testing directly on freshly resected tissue (skin, tumor, liver) following surgery or diagnosis (skin, blood, tumors, etc.) - 2D "in vitro" primary cell models: expertise human primary cell line production (immune cells, stem cells, cancer cells, liver cells, neuronal cells, skin cells, etc.) from fresh tissue for 2D bioassays - 3D bioprinting of human tissue: revolutionary technology enabling the industrialization of bioassay production, a faster, more accurate, reproducible, and highly automated process (10 years of R&D work carried out by CTIBIOTECH™). The result is a predictive 3D biological tissue structure composed of human cells that enables more reliable and cost-effective testing This innovative CRDMO business model offers: - Human cells and tissue bioassay products: turnkey high value technology solutions delivered to academic and industrial laboratories worldwide - Contract research and open innovation contract: for preclinical and clinical development for efficacy, potency and safety validation applied to biomedicine, pharmaceutical and dermatocosmetics R&D Composed of a team of 17 scientists, CTIBIOTECH™ operates a state-of-the art human tissue engineering and 3D bioprinting technical platform, composed of offices and laboratories, which hosts and operates an accredited and ISO 9001 certified human tissue biobank for scientific research

HEALTH INNOVATION RESEARCH / LAB / FUTURE